PARIS, Aug 27 (Reuters) - Clinical diagnostics company Novacyt ALNOV.PA, NCYT.L - one of many healthcare companies whose shares have surged during the pandemic - announced on Thursday a new product to allow people to differentiate the COVID-19 virus from common winter diseases.
Novacyt said its new 'Winterplex' test panel includes two gene targets specific to COVID-19, as well as gene targets for influenza A&B and respiratory syncytial virus (RSV).
"We believe Winterplex™ is one of the world’s first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases," Novacyt CEO Graham Mullis said.
(Reporting by Sudip Kar-Gupta; editing by Jason Neely)
((email@example.com; +33 1 49 49 53 84;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.